Abstracts tagged "osteoarthritis and viscosupplementation"

Abstract Number: 2004 • 2018 ACR/ARHP Annual Meeting
Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)
Cynthia Secchieri¹, Devis Galesso¹, Cristian Guarise¹, Mauro Pavan¹, Stefano Moro² and Veronica Salmaso², ¹Fidia Farmaceutici, Abano Terme, Italy, ²Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
Background/Purpose: Osteoarthritis (OA) is a disease which results in the degeneration of articular cartilage. The progression of OA involves inflammation in the early stage of…
Abstract Number: 980 • 2017 ACR/ARHP Annual Meeting
Is Intra-Articular Injection of Synvisc Associated with a Delay to Knee Arthroplasty in Knee OA Patients?
Kevin Ong¹, Maria Runa¹, Edmund Lau² and Roy Altman³, ¹Exponent, Inc., Philadelphia, PA, ²Exponent, Inc., Menlo Park, CA, ³UCLA Medical Center, Los Angeles, CA
Background/Purpose: Knee OA patients may undergo intra-articular (IA) hyaluronic acid (HA) injection treatment, but there is debate about its effectiveness. We asked: (1) What is…
Abstract Number: 290 • 2016 ACR/ARHP Annual Meeting
Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients
Thayer Mukherjee¹, Fernando Bomfim², Evan Wilder¹, Lauren Browne², Shira Aharon³, Kayleigh Toth¹, Eric Strauss⁴ and Jonathan Samuels⁵, ¹NYU Langone Medical Center, New York, NY, ²Rheumatology, NYU Langone Medical Center, New York, NY, ³NYU Langone Medical Center, Rheumatology, New York, NY, ⁴Orthopedic Surgery, NYU Langone Medical Center, New York, NY, ⁵Division of Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Hyaluronic acid (HA) viscosupplementation is widely used in patients with knee osteoarthritis (KOA), but variable reported outcomes have impacted its incorporation into treatment algorithms.…
Abstract Number: 2369 • 2016 ACR/ARHP Annual Meeting
Obesity and Severity of Joint Space Narrowing Are Associated with Viscosupplementation Failure in Patients with Knee Osteoarthritis. Post-Hoc Analysis of a Double-Blind, Controlled, Multicentre, Randomized Trial
Florent Eymard¹, Xavier Chevalier² and Thierry Conrozier³, ¹Department of Rheumatology, APHP Henri Mondor Hospital, Paris, France, ²Rheumatology, Hopital Henri Mondor, Créteil, France, ³Department of Rheumatology,, Nord Franche-Comté Hospital, Belfort, France
Background/Purpose: Viscosupplementation (VS) is still controversial. One of the key points is the lack of well-identified factors of response. We aimed to identify clinical…
Abstract Number: 76 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Intra-Articular Injection Of Alginate-Chitosan Beads In An Hydrogel Against The Development Of Experimental Osteoarthritis Lesions In Rabbit
Frédéric Oprenyeszk¹, Mickael Chausson², Véronique Maquet², Jean-Emile Dubuc³ and Yves Henrotin¹, ¹University of Liège, Bone and Cartilage Research Unit, Liège, Belgium, ²Parc industriel des Haut-Sarts, KitoZyme SA, Herstal, Belgium, ³Clinical University Saint Luc, Orthopaedic Department, Bruxelles, Belgium
Background/Purpose: Today, there is no treatment to cure osteoarthritis (OA) or to delay effectively its progression. Current treatments are mainly based on the alleviation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].